Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

President Donald Trump says he’ll sign an executive order on Monday intended to lower the cost of drugs in the U.S.

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

Quarter ResultsFormycon reports strong operational performance and financial results for first quarter of 2025 12.05.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of this ...

Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) - - Initiated CX-2051 Phase 1 ...

Three Motley Fool contributors believe you can. Here's why they think Axsome Therapeutics (NASDAQ: AXSM), Iovance ...

Even when equities are volatile, investors can find great stocks to buy. And the rules for investing in the current ...

Cancer specialists and patients have welcomed news that three potentially life-saving skin cancer medicines are to be funded.

Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results , but sales fell by 1.6% year on year to $15.53 ...